Business
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third
About this update from Phibro Animal Health Corporation
[{"type":"text","content":" TEANECK, N.J.--(BUSINESS WIRE)--\nPhibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2025, and its updated financial guidance for the year ending June 30, 2025.\n\nHighlights for the three months ended March 31, 2025 (compared to the three months ended March 31, 2024)\n\n\nNet sales of $347.8 million, an increase of $84.6 million, or 32%\n\n\nNet income of $20.9 million, an increase of $12.5 million\n\n\nDiluted earnings per share of $0.51, an increase of $0.30\n\n\nAdjusted EBITDA of $54.9 million, an increase of $25.2 million, or 85%\n\n\nAdjusted net income of $25.7 million, an increase of $13.0 million\n\n\nAdjusted diluted EPS of $0.63, an increase of $0.32\n\n\nWe have updated our fiscal year 2025 guidance, which includes:\n\n\nNet sales of $1.26 billion to $1.29 billion\n\n\nAdjusted EBITDA of $177 million to $183 million\n\n\nCOMMENTARY\n\n“Our strong performance this past quarter underscores the successful integration of the Zoetis MFA business and the initial positive impact of our Phibro Forward initiatives, where we are beginning to see benefits from actions such as SKU rationalization, enhanced procurement capabilities, and manufacturing improvements,\" stated Jack Bendheim, President and Chief Executive Officer. \"Despite temporary order timing that moderated growth in our legacy business, we achieved significant gains, with total sales increasing by 32%, and adjusted EBITDA and diluted EPS surging 85% and over 100%, respectively. Our overall Animal Health segment was a key driver, growing 42%, with MFA & Other product sales up 68% driven by the acquisition of the Zoetis MFA portfolio, while our legacy Animal Health business saw flat growth. Continued strong performance in our Nutritional specialty business was offset by the timing of orders in MFA and Other product sales, as well as Vaccines, which limited growth in the quarter. Mineral Nutrition and Performance Products delivered impressive year-over-year increases of 4% and 28%, respectively.\"\n\nRegarding tariffs, Mr. Bendheim added, \"While we are closely monitoring the situation, we do not foresee a material impact for the remainder of the fiscal year. We have identified potential effects on certain inputs and sales in the upcoming fiscal year based on current t...